Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

How GLP-1 analogs are reshaping diabetes care and obesity treatment and unlocking potential in cardiovascular, inflammatory, ...

Now some doctors are trying GLP-1 drugs — popular medications for weight-loss and Type 2 diabetes — as part of lymphedema ...

Semaglutide is an injectable medication that treats type 2 diabetes and obesity by regulating blood sugar levels. A ...

Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment First ...

GLP-1 and SGLT2 drugs — could significantly reduce the risk of developing dementia in life, a large new study has found.

According to Kiran Jones, a clinical pharmacist at Oxford Online Pharmacy, some of the most concerning side effects of GLP-1 ...

Susan Weiner, MS, RDN, CDN, CDCES, FADCES, talks with Linda Gigliotti, MS, RDN, CDCES, FAND, about combining the use of GLP-1 ...

Mounjaro, a new treatment for Type 2 diabetes and obesity, has been launched in India after CDSCO approval. The drug, ...

Amylyx Pharmaceuticals, Inc.’s AMLX share price has surged by 13.17%, which has investors questioning if this is right time to sell.

While GLP-1 receptor agonists are widely used to treat obesity ... There are five melanocortin receptors, MC1R through MC5R. Modulation of these receptors, through use of receptor-specific agonists, ...

Following this study, the Company plans to investigate AT-7687 as a combination therapy in patients treated with a GLP-1 receptor agonist ... of an endogenous GIPR antagonist by Professors ...